Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting.
Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.